Clinical Trial Update: Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated ciclesonide for improving quality of life in adults with moderate persistent asthma (ages 21 to 65). The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• ciclesonide (ciclesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED